101623-69-2

Basic information

• Product Name: Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester
• Synonyms: Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester;1-Chloroethyl (4-nitrophenyl) carbonate;1-Chloroethyl p-nitrophenyl carbonate
• CAS NO: 101623-69-2
• Molecular Formula: C₉H₈ClNO₅
• Molecular Weight: 245.61652
• Mol File: 101623-69-2.mol

Chemical Properties

• Melting Point: 71.0-71.7 °C(Solv: hexane (110-54-3))
• Boiling Point: 359.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.415±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester(101623-69-2)
• EPA Substance Registry System: Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester(101623-69-2)

Safety Data

• Hazardous Substances Data: 101623-69-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals for its role in facilitating the formation of essential chemical bonds.
Used in Fragrance and Flavor Industry:
Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester is utilized as a precursor in the production of esters, which are vital for creating distinct scents and tastes in the fragrance and flavor industry.
Used in Medicinal Chemistry and Drug Discovery:
Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester is employed in medicinal chemistry and drug discovery processes, where its reactivity in organic chemistry reactions aids in the development of new therapeutic agents.

Upstream product

• 100-02-7 4-nitro-phenol 
• 50893-53-3 carbonochloridic acid 1-chloro-ethyl ester 

Downstream Products

• 182747-25-7 1-(trimethylacetoxy)ethyl p-nitrophenyl carbonate 
• 1034191-20-2 C₂₅H₂₇NO₉ 
• 1034191-21-3 1-(((4-nitrophenoxy)carbonyl)oxy)ethyl benzoate 
• 1321458-96-1 1-((4-nitrophenoxy)carbonyloxy)ethyl-2, 2-dimethyl-3-(nitrooxy)propanoate 
• 1321458-86-9 1-((4-nitrophenoxy)carbonyloxy)ethyl 2-(2-(nitrooxy)ethoxy) acetate 
• 194995-47-6 1-[[(4-nitrophenoxy)carbonyl]oxy]-2-methylpropionic acid ethyl ester 
• 101623-68-1 1-{[(4-nitrophenoxy)carbonyl]oxy}ethyl acetate 
• 478296-69-4 1-iodoethyl 4-nitrophenyl carbonate 

Relevant articles and documents

Repeated dosing with NCX1404, a nitric oxide-donating pregabalin, re-establishes normal nociceptive responses in mice with streptozotocin-induced painful diabetic neuropathy

NCX1404 [(3S)-5-methyl-3-(((1-(4-(nitrooxy)butanoyloxy)ethoxy) carbonylamino) methyl)hexanoic acid] is a novel nitric oxide (NO)-donating pregabalin that is readily absorbed and processed in vivo to pregabalin and NO. We determined the antiallodynic response of NCX1404 after acute or after 7, 14, and 21 days of repeated daily oral dosing in mice with streptozotocin (STZ)-induced painful diabetic neuropathy (PDN). Pregabalin and its combination with the NO donor isosorbide mononitrate (ISMN) were used for comparison. The blood levels of pregabalin and nitrites, used as surrogate marker of NO release, after NCX1404 or pregabalin dosing were monitored in parallel experiments using liquid chromatography with tandem mass spectrometry (LC-MS/MS). NCX1404 and pregabalin resulted in similar pregabalin levels as it was their antiallodynic activity after acute dosing in STZ mice. However, NCX1404 resulted in disease-modifying properties when administered daily for 21 days, as indicated by the time- and dose-dependent reversal of STZ-induced mechanical allodynia (paw withdrawal threshold [PWT]Veh-21d = 1.3 v 0.15 g for vehicle; PWTNCX1404-21d = 1.4 ± 0.5 g, 2.9 ± 0.2 g? and 4.1 ± 0.2 g?, respectively for 19, 63, and 190 μmol/kg, oral gavage [PO] of NCX1404; ?P, 0.05 versus vehicle). This effect was not shared by pregabalin at equimolar doses (190 μmol/kg, PO, PWTPregab-21d = 1.4 ± 0.1 g?, ?P Veh-7d= 1.7 ± 0.16 g; PWTISMN-7d = 3.9 ± 0.34 g?; PWTPregab-7d = 1.3 ± 0.07 g; PWTISMN+pregab-7d = 3.8 ± 0.29 g?; ?P, 0.05) but not at later time points. The long-term effect of NCX1404 was independent of residual drug exposure and lasted for several days after the treatment was stopped. In summary, like pregabalin, NCX1404 is an effective antiallodynic agent. Differently from pregabalin, repeated dosing of NCX1404 re-established normal nociceptive responses in STZ-induced PDN in mice.

Macrocyclic prodrugs of a selective nonpeptidic direct thrombin inhibitor display high permeability, efficient bioconversion but low bioavailability

The only oral direct thrombin inhibitors that have reached the market, ximelagatran and dabigatran etexilat, are double prodrugs with low bioavailability in humans. We have evaluated an alternative strategy: the preparation of a nonpeptidic, polar direct

AZETIDINE DERIVATIVE, AND PRODRUG THEREOF

An object of the present invention is to provide a compound useful as a therapeutic or prophylactic drug for a disease involving the immune system, by suppressing a function of immune cells by suppressing proliferation of activated T cells or suppressing production of interferon alpha (IFN-α) by activated plasmacytoid dendritic cells (pDC), particularly an autoimmune disease such as systemic lupus erythematosus (SLE) and lupus nephritis in SLE patients. The present invention provides a compound represented by general formula (I) : [wherein X, R1, R2, R3, R4, R5 and R6 are as described in the description], or a pharmaceutically acceptable salt thereof.

PRODRUGS OF KALLIKREIN INHIBITORS

Disclosed are compounds of formula I, II, and III, and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein. Also provided are pharmaceutical compositions comprising such a compound, and methods involving use of the compounds and compositions in the treatment and prevention of acquired or hereditary angioedema, or other diseases and conditions characterized by aberrant kallikrein activity. (I) (II) (III)

Pharmaceutical composition for the treatment or prevention of stroke and systemic embolism

The present invention relates to a prodrug useful for treating or preventing a stroke and systemic embolism and suitable for being effectively used in the oral delivery of dabigatran, and to a compound represented by chemical formula 1, a pharmaceutically acceptable salt thereof, and a hydrate thereof or a solvate thereof. The compound represented by the chemical formula 1, the pharmaceutically acceptable salt thereof, and the hydrate thereof or the solvate thereof are useful for treating or preventing a stroke and systemic embolism, and is suitable for being effectively used in oral delivery since the absorption rate, that is, bioavailability of dabigatran is improved.(AA) DSC curve of dabigatran pivoxyl (+)-(1S)- campo-10-sulfonateCOPYRIGHT KIPO 2015

NITRIC OXIDE RELEASING COMPOUNDS FOR THE TREATMENT OF NEUROPHATIC PAIN

The present invention relates to nitric oxide releasing derivatives of serotonin norepinephrine reuptake inhibitors and their use for the treatment of pain, having the following general formula (I) or pharmaceutically acceptable salts thereof: wherein : A is selected from the formulas (1a) and (1b). The present invention also relates to pharmaceutical formulation comprising such derivatives, to a process for their preparation and to intermediates useful for their preparation.

NITRIC OXIDE RELEASING COMPOUNDS FOR THE TREATMENT OF NEUROPATHIC PAIN

The invention relates to nitrooxyderivatives of Gamma- aminobutyric acid analogs (GABA analogs) for treating neuropathic pain and in particular diabetic neuropathy. The invention also relates to pharmaceutical formulation comprising such derivatives, to a process for their preparation.

PROCESSES FOR THE PREPARATION AND PURIFICATION OF GABAPENTIN ENACARBIL

Gabapentin enacarbil was prepared and purified from intermediates such as 1- haloalkyl carbamate or carbonate and diacid acetal skeleton. For example, a 1-haloalkyl carbonate or carbamate was prepared by combining a C1 to C 10 alcohol or C1 to C10 primary amine, a solvent selected from the group consisting of: acetonitrile, C3 to C7 ketone, C5 to C 10 ether, C2 to C7 ester, C5 to C 10 hydrocarbon and a combination thereof; a 1-haloalkyl halo formate of the following formula:(I) wherein each X is independently selected from Br, I, or Cl; R1 is alkyl or H; and a C6 to C21 tertiary amine.

Effect of potential amine prodrugs of selective neuronal nitric oxide synthase inhibitors on blood-brain barrier penetration

Several prodrug approaches were taken to mask amino groups in two potent and selective neuronal nitric oxide synthase (nNOS) inhibitors containing either a primary or secondary amino group to lower the charge and improve blood-brain barrier (BBB) penetration. The primary amine was masked as an azide and the secondary amine as an amide or carbamate. The azide was not reduced to the amine under a variety of in vitro and ex vivo conditions. Despite the decrease in charge of the amino group as an amide and as carbamates, BBB penetration did not increase. It appears that the uses of azides as prodrugs for primary amines or amides and carbamates as prodrugs for secondary amines are not universally effective for CNS applications.

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.